Wells Fargo’s Strongbridge Biopharma plc. SBBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-13,203
| Closed | -$27K | – | 8315 |
|
|
2021
Q3 | $27K | Sell |
13,203
-15
| -0.1% | -$35 | ﹤0.01% | 5870 |
|
|
2021
Q2 | $39K | Sell |
13,218
-553,916
| -98% | -$1.46M | ﹤0.01% | 5659 |
|
|
2021
Q1 | $1.57M | Buy |
567,134
+371,956
| +191% | +$1.12M | ﹤0.01% | 3913 |
|
|
2020
Q4 | $475K | Buy |
195,178
+52,610
| +37% | +$127K | ﹤0.01% | 4560 |
|
|
2020
Q3 | $300K | Buy |
142,568
+23,469
| +20% | +$79.1K | ﹤0.01% | 4717 |
|
|
2020
Q2 | $451K | Buy |
119,099
+14,039
| +13% | +$42.1K | ﹤0.01% | 4405 |
|
|
2020
Q1 | $199K | Buy |
105,060
+13,980
| +15% | +$36.3K | ﹤0.01% | 4699 |
|
|
2019
Q4 | $192K | Buy |
91,080
+5,517
| +6% | +$10.6K | ﹤0.01% | 4975 |
|
|
2019
Q3 | $204K | Buy |
85,563
+32,211
| +60% | +$86.5K | ﹤0.01% | 4952 |
|
|
2019
Q2 | $168K | Sell |
53,352
-27,330
| -34% | -$100K | ﹤0.01% | 5070 |
|
|
2019
Q1 | $401K | Buy |
80,682
+13,513
| +20% | +$66.5K | ﹤0.01% | 4460 |
|
|
2018
Q4 | $300K | Buy |
67,169
+24,318
| +57% | +$119K | ﹤0.01% | 4674 |
|
|
2018
Q3 | $207K | Buy |
42,851
+630
| +1% | +$3.22K | ﹤0.01% | 4983 |
|
|
2018
Q2 | $253K | Sell |
42,221
-81,127
| -66% | -$594K | ﹤0.01% | 4902 |
|
|
2018
Q1 | $1.09M | Buy |
123,348
+78,708
| +176% | +$589K | ﹤0.01% | 3844 |
|
|
2017
Q4 | $324K | Buy |
44,640
+41,012
| +1,130% | +$256K | ﹤0.01% | 4701 |
|
|
2017
Q3 | $24K | Buy |
+3,628
| New | +$25K | ﹤0.01% | 5672 |
|
Wells Fargo's SBBP Position: Q4 2021 in Review
Wells Fargo sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 13,203 shares — an estimated $27K sold.
Wells Fargo first reported a position in SBBP in Q3 2017 and held it in 17 quarters. The position peaked at $1.57M in Q1 2021. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.
- Wells Fargo reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
- Wells Fargo sold 13,203 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $27K.
- Wells Fargo first reported a position in Strongbridge Biopharma plc. in Q3 2017 and held it in 17 quarters.
- Wells Fargo's Strongbridge Biopharma plc. position peaked at $1.57M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.
Based on Wells Fargo's 13F filing for Q4 2021, filed 14 Feb 2022.